Salud financiera de hoja de balance de Viva Biotech Holdings
Salud financiera controles de criterios 4/6
Viva Biotech Holdings tiene un patrimonio de accionistas total de CN¥3.8B y una deuda total de CN¥1.5B, lo que sitúa su ratio deuda-patrimonio en 39.8%. Sus activos y pasivos totales son CN¥7.2B y CN¥3.4B respectivamente. El BAIT de Viva Biotech Holdings es de CN¥184.7M, por lo que su ratio de cobertura de intereses es de 1.9. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥1.0B.
Información clave
39.8%
Ratio deuda-patrimonio
CN¥1.51b
Deuda
| Ratio de cobertura de intereses | 1.9x |
| Efectivo | CN¥1.04b |
| Patrimonio | CN¥3.80b |
| Total pasivo | CN¥3.38b |
| Activos totales | CN¥7.18b |
Actualizaciones recientes sobre salud financiera
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 14
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 01These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way
Sep 25These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively
Apr 14Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?
Nov 06We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt
Apr 17Recent updates
Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth
Oct 14Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel
Aug 30Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely
Jun 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 14Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely
May 03A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Apr 26Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump
Jan 19Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?
Jun 01These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way
Sep 25Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?
Jul 11These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively
Apr 14Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?
Dec 23Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?
Nov 06Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)
Jun 13We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt
Apr 17Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain
Mar 13Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares
Feb 06What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?
Jan 02Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?
Nov 21
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥1.9B) de 1873 superan a sus pasivos a corto plazo (CN¥1.2B).
Pasivo a largo plazo: Los activos a corto plazo (CN¥1.9B) de 1873 no cubren sus pasivos a largo plazo (CN¥2.2B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (12.5%) de 1873 se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de 1873 ha crecido de 0.1% a 39.8% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable 1873 tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: 1873 no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 22.3% al año.